Skip to main content
Premium Trial:

Request an Annual Quote

Inscripta Raises $125M in Series D Financing Round

NEW YORK – Gene editing company Inscripta announced on Tuesday that it has raised $125 million in a Series D financing round.

Paladin Capital Group led the round, with support from existing investors and new investors JS Capital Management and Oak HC/FT. The company said it has now raised $259.5 million — its Series C round raised a total of $105.5 million after two expansions.

Inscripta said it plans to use the new funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform, as well as for commercialization of the platform. The company unveiled the platform in June, calling it the first automated benchtop instrument that can write genomic modifications into any location within the genome in a rationally controlled and precise manner, with no random side effects.

"We're introducing single-cell writing technology," Inscripta CEO Kevin Ness said at the time.

In a statement on the new funding round, Ness said the additional financing will allow the company to meet the anticipated need for its platform.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more